BlueWind Medical
BlueWind Medical develops the Revi system, a miniature, implantable device for Urge Urinary Incontinence that uses drug-free neuromodulation therapy.
Secondary Market Price
How BlueWind Medical Measures Up
To help you manage your BlueWind Medical equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of BlueWind Medical's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future BlueWind Medical Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for BlueWind Medical's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
BlueWind Medical is a medical device company centered on its flagship product, the Revi system, which is a minimally invasive, implantable device for the treatment of urge urinary incontinence (UUI). The company is currently engaged in marketing the Revi system to patients and healthcare providers, offering educational content and support resources related to the treatment journey and insurance coverage. While a detailed company history is not publicly available, a key milestone was the completion of the pivotal OASIS study, which assessed the efficacy and safety of the Revi system.
The company's ongoing clinical studies and development of support resources suggest a continued focus on research and market expansion for the Revi system. A notable recent development is the Revi system winning the 'Best New Technology Solution – Therapeutics' at the 2025 MedTech Breakthrough Awards. Furthermore, the two-year results from the OASIS clinical study were published in the Journal of Urology in March 2025. The study data showed high patient satisfaction and a significant reduction in urinary leaks for a majority of participants.
- ConvaTec
- Rainbow Medical
- Highlight Capital
- Medtronic
- Co-Founder, Yossi Gross
- Co-Founder, Efi Cohen Arazi
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is BlueWind Medical worth joining?
Deciding whether to join any startup depends on your personal career goals and how the company's equity package aligns with your financial objectives. A platform like Prospect can help you make an informed decision by comparing the potential value of your equity offer against opportunities at other private companies.
What should I do with my BlueWind Medical stock?
The best strategy for your private stock depends on your personal financial situation, risk tolerance, and tax circumstances. Platforms like Prospect can build a customized, multi-year plan for exercising options and selling shares to help you maximize your potential earnings.
Can you sell BlueWind Medical stock?
As BlueWind Medical is a private company, you can typically only sell shares during specific liquidity events, such as a tender offer or on a secondary market. Resources like Prospect offer tender offer tools that help you decide how much to sell and which shares are the most tax-efficient to offload.
How can I find the value of my BlueWind Medical stock?
Valuing stock in a private company is challenging because its worth is not readily available on a public market. Platforms like Prospect use proprietary predictive models, similar to those used by VCs, to forecast the future value of your shares.
What is BlueWind Medical's equity worth?
The precise worth of private company equity fluctuates based on factors like company performance, market conditions, and recent funding rounds. To get a data-driven estimate, you can use tools from a platform like Prospect to project a range of potential outcomes for your equity's value.
What is BlueWind Medical's stock ticker symbol?
Since BlueWind Medical is a private company, it is not listed on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO) and their shares are available for public trading.
Can I buy or sell BlueWind Medical stock?
Buying stock in a private company is typically restricted to accredited investors during funding rounds, while employees acquire shares by exercising stock options. Selling is possible during liquidity events like tender offers, and platforms like Prospect provide tools to create tax-optimal strategies for both exercising and selling.
What is the criteria to buy or invest in BlueWind Medical stock?
Investing in a private company like BlueWind Medical is generally limited to accredited investors in financing rounds or employees who receive equity compensation. For employees making decisions about their equity, platforms like Prospect help evaluate the investment by modeling scenarios and analyzing potential returns.
